{"doi":"10.1111/hiv.70257","title":"Hodgkin and non‐Hodgkin lymphomas in the post‐antiretroviral therapy era according to\n                    <scp>HIV</scp>\n                    virological suppression","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives</jats:title>\n                    <jats:p>Lymphomas remain among the most frequent HIV‐associated malignancies, with risk persisting despite effective virological control.</jats:p>\n                    <jats:p>This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non‐Hodgkin [NHL]) in people living with HIV (PLWH), according to virological suppression at diagnosis and assesses lymphoma‐related mortality at 1 year and overall survival at 5 years.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>We conducted a multicentre retrospective study including PLWH from the Spanish CoRIS cohort, who were diagnosed with lymphoma between 2004 and 2022 and had HIV viral load data at diagnosis. Virological suppression was defined as HIV‐1 RNA &lt;100 copies/mL within the 6 months prior to and 1 month following lymphoma diagnosis.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>\n                      Among 18 573 PLWH included in CoRIS, 291 developed lymphoma, with virological data available for 245 individuals, of whom 49 (20%) had virological suppression. People with detectable HIV viral load had lower CD4 counts (median 180 cells/mm\n                      <jats:sup>3</jats:sup>\n                      [IQR 80–330] vs. 371 cells/mm\n                      <jats:sup>3</jats:sup>\n                      [IQR 202–583],\n                      <jats:italic>p</jats:italic>\n                       &lt; 0.001) and more advanced Ann Arbor stage (stage III–IV: 82.0% vs. 64.1%,\n                      <jats:italic>p</jats:italic>\n                       = 0.027) compared with those with virological suppression. Despite this, they showed similar treatment response (complete remission: 67.1% vs. 76.2%) and relapse rates (16.3% vs. 18.4%,\n                      <jats:italic>p</jats:italic>\n                       = 0.779). Furthermore, virological suppression was not independently associated with 1‐year lymphoma‐specific or 5‐year overall survival.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>In PLWH diagnosed with lymphoma, prognosis is independent of HIV virological status at diagnosis. These findings support that lymphoma management in PLWH should be guided by standard oncological criteria, alongside antiretroviral therapy, regardless of HIV viral suppression status.</jats:p>\n                  </jats:sec>","journal":"HIV Medicine","year":2026,"id":630324,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1632872,"name":"Francisco Tejerina","orcid":null,"position":1,"is_corresponding":false},{"id":1632873,"name":"Chiara Fanciulli","orcid":null,"position":2,"is_corresponding":false},{"id":1632875,"name":"Cristina Diez","orcid":null,"position":3,"is_corresponding":false},{"id":1632877,"name":"Leire Perez","orcid":null,"position":4,"is_corresponding":false},{"id":1632878,"name":"José Maria Bellón","orcid":null,"position":5,"is_corresponding":false},{"id":1632880,"name":"Nuria Espinosa","orcid":null,"position":6,"is_corresponding":false},{"id":1521787,"name":"Santiago Moreno Guillén","orcid":null,"position":7,"is_corresponding":false},{"id":1632882,"name":"Maria del Mar Arcos‐Rueda","orcid":"0000-0002-9961-5544","position":8,"is_corresponding":false},{"id":490448,"name":"Marta Montero","orcid":"0000-0002-3432-5394","position":9,"is_corresponding":false},{"id":747140,"name":"Lucio García‐Fraile","orcid":"0000-0002-2512-6107","position":10,"is_corresponding":false},{"id":1360417,"name":"Víctor Asensi","orcid":"0000-0003-4211-456X","position":11,"is_corresponding":false},{"id":1632883,"name":"Marian Fernández López","orcid":null,"position":12,"is_corresponding":false},{"id":1632884,"name":"Diana Corona‐Mata","orcid":null,"position":13,"is_corresponding":false},{"id":83449,"name":"Alfonso Cabello","orcid":"0000-0001-8429-8358","position":14,"is_corresponding":false},{"id":1632885,"name":"Meritxell Gavaldà Manso","orcid":"0000-0003-4663-8117","position":15,"is_corresponding":false},{"id":1632886,"name":"Jose Antonio Iribarren","orcid":null,"position":16,"is_corresponding":false},{"id":1632887,"name":"Laura Pérez‐Martínez","orcid":null,"position":17,"is_corresponding":false},{"id":1632888,"name":"María Remedios Alemán Valls","orcid":null,"position":18,"is_corresponding":false},{"id":1632889,"name":"Irene Portilla‐Tamarit","orcid":"0000-0002-2187-8731","position":19,"is_corresponding":false},{"id":1632890,"name":"Joaquim Peraire","orcid":null,"position":20,"is_corresponding":false},{"id":1632891,"name":"Inés Suárez‐García","orcid":"0000-0002-7016-716X","position":21,"is_corresponding":false},{"id":441503,"name":"Mar Masiá","orcid":"0000-0001-9878-2458","position":22,"is_corresponding":false},{"id":1632892,"name":"María José Núñez Orantos","orcid":"0000-0002-6715-590X","position":23,"is_corresponding":false},{"id":1351537,"name":"Ángela Gutiérrez","orcid":"0000-0003-0217-5122","position":24,"is_corresponding":false},{"id":370685,"name":"Arkaitz Imaz","orcid":"0000-0001-8411-1952","position":25,"is_corresponding":false},{"id":1632893,"name":"Cristina Hernández Gutiérrez","orcid":null,"position":26,"is_corresponding":false},{"id":1632894,"name":"Maria Tasias Pitarch","orcid":null,"position":27,"is_corresponding":false},{"id":1549904,"name":"Marta Rava","orcid":"0000-0003-2260-9370","position":28,"is_corresponding":false},{"id":1632870,"name":"Teresa Aldámiz‐Echevarria","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Hodgkin and non‐Hodgkin lymphomas in the post‐antiretroviral therapy era according to\n                    <scp>HIV</scp>\n                    virological suppression","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives</jats:title>\n                    <jats:p>Lymphomas remain among the most frequent HIV‐associated malignancies, with risk persisting despite effective virological control.</jats:p>\n                    <jats:p>This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non‐Hodgkin [NHL]) in people living with HIV (PLWH), according to virological suppression at diagnosis and assesses lymphoma‐related mortality at 1 year and overall survival at 5 years.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>We conducted a multicentre retrospective study including PLWH from the Spanish CoRIS cohort, who were diagnosed with lymphoma between 2004 and 2022 and had HIV viral load data at diagnosis. Virological suppression was defined as HIV‐1 RNA &lt;100 copies/mL within the 6 months prior to and 1 month following lymphoma diagnosis.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>\n                      Among 18 573 PLWH included in CoRIS, 291 developed lymphoma, with virological data available for 245 individuals, of whom 49 (20%) had virological suppression. People with detectable HIV viral load had lower CD4 counts (median 180 cells/mm\n                      <jats:sup>3</jats:sup>\n                      [IQR 80–330] vs. 371 cells/mm\n                      <jats:sup>3</jats:sup>\n                      [IQR 202–583],\n                      <jats:italic>p</jats:italic>\n                       &lt; 0.001) and more advanced Ann Arbor stage (stage III–IV: 82.0% vs. 64.1%,\n                      <jats:italic>p</jats:italic>\n                       = 0.027) compared with those with virological suppression. Despite this, they showed similar treatment response (complete remission: 67.1% vs. 76.2%) and relapse rates (16.3% vs. 18.4%,\n                      <jats:italic>p</jats:italic>\n                       = 0.779). Furthermore, virological suppression was not independently associated with 1‐year lymphoma‐specific or 5‐year overall survival.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>In PLWH diagnosed with lymphoma, prognosis is independent of HIV virological status at diagnosis. These findings support that lymphoma management in PLWH should be guided by standard oncological criteria, alongside antiretroviral therapy, regardless of HIV viral suppression status.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"42144866","pmcid":null,"openalex_id":"https://openalex.org/W7161564229","authors":[],"funders":[{"funder_name":"CIBER-Consorcio Centro de Investigación Biomédica en Red","grant_id":"CB21/13/00091","title":null},{"funder_name":"Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU","grant_id":"","title":null},{"funder_name":"Instituto de Salud Carlos III","grant_id":"","title":null},{"funder_name":"Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU","grant_id":"","title":null}],"total_grants":4,"fwci":0.0,"citation_percentile":0.49198232,"influential_citations":0,"citation_trend":[],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1111/hiv.70257","host_type":"journal"},{"url":"https://doi.org/10.1111/hiv.70257","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.70257","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/hiv.70257","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/42144866","host_type":"repository"}],"fields_of_study":["Viral-associated cancers and disorders","Lymphoma Diagnosis and Treatment","HIV Research and Treatment","Humans","Female","Retrospective Studies","Viral Load","HIV Infections","Male","Spain","Lymphoma, Non-Hodgkin","Adult","Middle Aged","Hodgkin Disease","Prognosis","CD4 Lymphocyte Count","Lymphoma, AIDS-Related"],"mesh_terms":["Adult","Female","Hodgkin Disease","Humans","Lymphoma, Non-Hodgkin","Male","Middle Aged","Prognosis","Retrospective Studies","Spain","HIV Infections","Lymphoma, AIDS-Related","CD4 Lymphocyte Count","Viral Load"],"keywords":["Lymphoma","Viral load","Epidemiology","Human immunodeficiency virus (HIV)","Hodgkin lymphoma","Antiretroviral therapy","Retrospective cohort study","Hiv‐associated Malignancies"," Survival"," Virological Suppression "],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T20:56:17.136292Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}